Biomedical Test Calibration Application and Research Center, Izmir Katip Celebi University, Çiğli, Izmir 35620, Turkey; Department of Biomedical Technologies, Graduate School of Natural and Applied Sciences, Izmir Katip Celebi University, Çiğli, Izmir 35620, Turkey.
Biomedical Test Calibration Application and Research Center, Izmir Katip Celebi University, Çiğli, Izmir 35620, Turkey; Department of Biomedical Technologies, Graduate School of Natural and Applied Sciences, Izmir Katip Celebi University, Çiğli, Izmir 35620, Turkey; Department of Biomedical Engineering, Faculty of Engineering and Architecture, Izmir Katip Celebi University, Çiğli, Izmir 35620, Turkey.
Biomater Adv. 2023 Jun;149:213392. doi: 10.1016/j.bioadv.2023.213392. Epub 2023 Mar 20.
Bone tissue engineering aims to diversify and enhance the strategies for bone regeneration to overcome bone-related health problems. Bone mimetic peptides such as Gly-Arg-Gly-Asp-Ser (RGD) are useful tools for osteogenic differentiation. Similarly, photobiomodulation (PBM) at 600-800 nm of wavelength range improves bone tissue healing via the production of intracellular reactive oxygen species (ROS), ATP synthesis, and nitric oxide (NO) release. Besides, traditional monolayer cell culture models have limited conditions to exhibit the details of a mechanism such as a peptide or PBM therapy. However, scaffold-free microtissues (SFMs) can mimic a tissue more properly and be an efficient way to understand the mechanism of therapy via cell-cell interaction. Thus, the synergistic effects of RGD peptide (1 mM) and PBM applications (1 J/cm energy density at 655 nm of wavelength and 5 J/cm energy density at 808 nm of wavelength) were evaluated on SFMs formed with the co-culture of Human Bone Marrow Stem Cells (hBMSC) and Human Umbilical Vein Endothelial Cells (HUVEC) for osteogenic differentiation. Cell viability assays, mechanistic analysis, and the evaluation of osteogenic differentiation markers were performed. Combined therapies of RGD and PBM were more successful to induce osteogenic differentiation than single therapies. Especially, RGD + PBM at 655 nm group exhibited a higher capability of osteogenic differentiation via ROS production, ATP synthesis, and NO release. It can be concluded that the concomitant use of RGD and PBM may enhance bone regeneration and become a promising therapeutic tool to heal bone-related problems in clinics.
骨组织工程旨在多样化和增强骨再生策略,以克服与骨骼相关的健康问题。甘氨酰-精氨酰-甘氨酰-天冬氨酸-丝氨酸(RGD)等骨模拟肽是成骨分化的有用工具。同样,波长范围在 600-800nm 的光生物调节(PBM)通过产生细胞内活性氧(ROS)、ATP 合成和一氧化氮(NO)释放来改善骨组织愈合。此外,传统的单层细胞培养模型在展示肽或 PBM 治疗等机制的细节方面条件有限。然而,无支架微组织(SFMs)可以更恰当地模拟组织,并且通过细胞-细胞相互作用是理解治疗机制的有效方法。因此,评估了 RGD 肽(1mM)和 PBM 应用(波长 655nm 时为 1J/cm 的能量密度和波长 808nm 时为 5J/cm 的能量密度)对由人骨髓间充质干细胞(hBMSC)和人脐静脉内皮细胞(HUVEC)共培养形成的 SFMs 的协同作用在成骨分化中的作用。进行了细胞活力测定、机制分析和骨分化标志物的评估。与单一疗法相比,RGD 和 PBM 的联合治疗更能成功地诱导成骨分化。特别是,RGD+PBM 在 655nm 组通过 ROS 产生、ATP 合成和 NO 释放表现出更高的成骨分化能力。可以得出结论,RGD 和 PBM 的同时使用可能会增强骨再生,并成为治疗与骨骼相关问题的有前途的治疗工具。